Erken evre Hodgkin hastalığı: Erciyes Üniversitesi deneyimi

Serdar SOYUER, Eray KARAHACIOĞLU, H. Şenol COŞKUN, Bülent ESER, Ali ÜNAL, Mustafa ÇETİN, Mustafa ALTINBAŞ, Özlem ER

Özet

Amaç: Hodgkin hastalığı (HH) yeni tam konulan malign hastalıkların yaklaşık %1 'ini oluşturur. Çalışmada erken evre HH tedavisi değerlendirildi. Hastalar ve Yöntem: Takip edilen 119 HH olgusu içerisinde erken evre 30 olgu retrospektif olarak değerlendirildi. Erken evre olarak evre IA, IB, ve HA kabul edildi. Bulgular: Erken evre olguların tüm hastalara oranı 30/119 (%25.2) olarak bulundu. On hasta (%8.4) evre IA, 2 hasta

Abstract

Purpose: Hodgkin's disease (HD) accounts for about 1% of newly diagnosed malignant diseases annually. In this study, we evaluated the treatment of early stage HD. Patients and Method: Thirty early stage cases out of 119 Hodgkin's disease patients were evaluated retrospectively. Stage IA, IB, and HA were accepted as the early stage. Results: The ratio of early stage to total, patients was 30/119 (25.2%). Ten patients were stage IA, 2 patients stage IB and 18 patients stage IIA. Twenty-two patients were male, 8 patients female and the median follow up period was 30 months (range 6-120). Median age of the patients was 37.5 years (range 16-72). According to histopathological classifications, 11 patients were lymphocyte predominant type, 7 patients mixed cellularity type and 12 patients nodular sclerosing type. Radiotherapy alone was used in 20 patients. Two patients in stage IB and 7 patients in stage IIA received COPP, and 1 patient in stage IIA COPP/ABVD as the alternating regimen. Complete remission was obtained in 28 patients (93.3%). Relapse was detected in 13 (43.3%) patients and 2 died during follow up. The estimated five years overall survival rate was 90.8% and progression free survival 21.3%. Conclusion: Combined modalities with chemotherapy and radiotherapy should be used in the treatment of early stage HD.